Journal of Cancer Research and Clinical Oncology

, Volume 138, Issue 2, pp 231–238

A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer

  • Jian Cheng
  • Minwen Ha
  • Yadi Wang
  • Jing Sun
  • Junchen Chen
  • Yue Wang
  • Chunyan Tong
Original Paper

DOI: 10.1007/s00432-011-1090-1

Cite this article as:
Cheng, J., Ha, M., Wang, Y. et al. J Cancer Res Clin Oncol (2012) 138: 231. doi:10.1007/s00432-011-1090-1

Abstract

Purpose

To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C → T), and the response of patients with late-stage non-small cell lung cancer (NSCLC) (n = 142) to cisplatin-based chemotherapy.

Methods

The SNP, Asn118Asn (C → T), in codon 118 of ERCC1 was detected using an AllGlo™ Probe-based real-time PCR kit. The short-term clinical outcomes were evaluated by measuring complete and partial responses (CR and PR), whereas progression-free survival (PFS) and overall survival (OS) were determined to indicate long-term outcomes.

Results

The allelic frequencies of the ERCC1 codon 118 were found to be 60.6% (C/C), 33.1% (C/T), and 6.3% (T/T), respectively. Overall, the CR and PR to cisplatin-based treatment were 33.1%. Notably, the response rate of patients carrying an ERCC1 118 C/C allele was more than twofold higher than that of patients with a C/T or T/T genotype (95% confidence interval (CI), 1.065–3.910, P = 0.032). Correspondingly, the long-term median PFS and OS of patients carrying the ERCC1 118 C/C allele were significantly longer than those of patients carrying a C/T or T/T allele (P < 0.01). Besides, positive correlation was observed between the differentiation status and tumor staging as well as the C/C genotype.

Conclusions

Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. Moreover, by assaying this SNP in blood cells, the ERCC1 codon 118 may represent a valuable biomarker in developing individualized treatments for NSCLC patients.

Keywords

ERCC1PolymorphismsCisplatinNon-small cell lung cancer

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Jian Cheng
    • 1
  • Minwen Ha
    • 1
  • Yadi Wang
    • 1
  • Jing Sun
    • 2
  • Junchen Chen
    • 1
  • Yue Wang
    • 1
  • Chunyan Tong
    • 3
  1. 1.Department of OncologyFirst Affiliated Hospital of Liaoning Medical UniversityJinzhouChina
  2. 2.Affiliated Hospital of Binzhou Medical UniversityBinzhouChina
  3. 3.Dalian Medical UniversityDalianChina